AstraZeneca defends COVID-19 vaccine, says ‘no evidence’ of increased risk of blood clots

AstraZeneca Plc on Sunday said it had conducted a review of people vaccinated with its COVID-19 vaccine which has shown no evidence of an increased risk of blood clots.

The review covered more than 17 million people vaccinated in the European Union and United Kingdom.

“A careful review of all available safety data of more than 17 million people vaccinated in the European Union and UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” the statement said.

Global News has reached out to see if Health Canada was considering halting its AstraZeneca vaccine rollout or had requested any additional data from its clinical trials, but did not immediately hear back.

More to come.

Story continues below advertisement

— With files from Global News’ Hannah Jackson and Emerald Bensadoun

© 2021 Reuters

Latest articles

Related articles